scholarly journals AMPA- and NMDA-Associated Postsynaptic Protein Expression in the Human Dorsolateral Prefrontal Cortex

2003 ◽  
Vol 1003 (1) ◽  
pp. 352-355 ◽  
Author(s):  
MONICA BENEYTO ◽  
JAMES H. MEADOR-WOODRUFF
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anita L. Pinner ◽  
Toni M. Mueller ◽  
Khaled Alganem ◽  
Robert McCullumsmith ◽  
James H. Meador-Woodruff

AbstractThe pathophysiology of schizophrenia includes altered neurotransmission, dysregulated intracellular signaling pathway activity, and abnormal dendritic morphology that contribute to deficits of synaptic plasticity in the disorder. These processes all require dynamic protein–protein interactions at cell membranes. Lipid modifications target proteins to membranes by increasing substrate hydrophobicity by the addition of a fatty acid or isoprenyl moiety, and recent evidence suggests that dysregulated posttranslational lipid modifications may play a role in multiple neuropsychiatric disorders, including schizophrenia. Consistent with these emerging findings, we have recently reported decreased protein S-palmitoylation in schizophrenia. Protein prenylation is a lipid modification that occurs upstream of S-palmitoylation on many protein substrates, facilitating membrane localization and activity of key intracellular signaling proteins. Accordingly, we hypothesized that, in addition to palmitoylation, protein prenylation may be abnormal in schizophrenia. To test this, we assayed protein expression of the five prenyltransferase subunits (FNTA, FNTB, PGGT1B, RABGGTA, and RABGGTB) in postmortem dorsolateral prefrontal cortex from patients with schizophrenia and paired comparison subjects (n = 13 pairs). We found decreased levels of FNTA (14%), PGGT1B (13%), and RABGGTB (8%) in schizophrenia. To determine whether upstream or downstream factors may be driving these changes, we also assayed protein expression of the isoprenoid synthases FDPS and GGPS1 and prenylation-dependent processing enzymes RCE and ICMT. We found these upstream and downstream enzymes to have normal protein expression. To rule out effects from chronic antipsychotic treatment, we assayed FNTA, PGGT1B, and RABGGTB in the cortex from rats treated long-term with haloperidol decanoate and found no change in the expression of these proteins. Given the role prenylation plays in localization of key signaling proteins found at the synapse, these data offer a potential mechanism underlying abnormal protein–protein interactions and protein localization in schizophrenia.


2019 ◽  
Author(s):  
Anita L. Pinner ◽  
Toni M. Mueller ◽  
Khaled Alganem ◽  
Robert McCullumsmith ◽  
James H. Meador-Woodruff

AbstractThe pathophysiology of schizophrenia includes altered neurotransmission, dysregulated intracellular signaling pathway activity, and abnormal dendritic morphology that contribute to deficits of synaptic plasticity in the disorder. These processes all require dynamic protein-protein interactions at cell membranes. Lipid modifications target proteins to membranes by increasing substrate hydrophobicity by the addition of a fatty acid or isoprenyl moiety, and recent evidence suggests that dysregulated post-translational lipid modifications may play a role in multiple neuropsychiatric disorders including schizophrenia. Consistent with these emerging findings, we have recently reported decreased protein S-palmitoylation in schizophrenia. Protein prenylation is a lipid modification that occurs upstream of S-palmitoylation on many protein substrates, facilitating membrane localization and activity of key intracellular signaling proteins. Accordingly, we hypothesized that in addition to palmitoylation, protein prenylation may be abnormal in schizophrenia. To test this, we assayed protein expression of the five prenyltransferase subunits (FNTA, FNTB, PGGT1B, RABGGTA, and RABGGTB) in postmortem dorsolateral prefrontal cortex from patients with schizophrenia and paired comparison subjects (N = 13 pairs). We found decreased levels of FNTA (14%), PGGT1B (13%), and RABGGTB (8%) in schizophrenia. To determine if upstream or downstream factors may be driving these changes, we also assayed protein expression of the isoprenoid synthases FDPS and GGPS1, and prenylation-dependent processing enzymes REC and ICMT. We found these upstream and downstream enzymes to have normal protein expression. To rule out effects from chronic antipsychotic treatment, we assayed FNTA, PGGT1B and RABGGTB in cortex from rats treated long-term with haloperidol decanoate, and found no change in the expression of these proteins. Given the role prenylation plays in localization of key signaling proteins found at the synapse, these data offer a potential mechanism underlying abnormal protein-protein interactions and protein localization in schizophrenia.


2018 ◽  
Vol 15 (3) ◽  
pp. 796-806 ◽  
Author(s):  
María S. García-Gutiérrez ◽  
Francisco Navarrete ◽  
Gemma Navarro ◽  
Irene Reyes-Resina ◽  
Rafael Franco ◽  
...  

2021 ◽  
Author(s):  
Ganesh B Chand ◽  
Hao Jiang ◽  
Matthew Brier ◽  
Farzaneh Rahmani ◽  
Tammie L. S. Benzinger ◽  
...  

There is growing evidence that there are subtypes of schizophrenia (Bowen et al., 2019; Chand et al., 2020). Specifically, messenger ribonucleic acid (mRNA) gene expression findings on postmortem dorsolateral prefrontal cortex (DLPFC) suggest that schizophrenia patients can be divided into two groups, those with a relatively normal DLPFC transcriptome (Type 1) and those with hundreds of differentially expressed genes (Type 2). The clinical relevance of that finding is limited by the fact that autopsy tissue is required to distinguish Type 1 from Type 2 patients, however the PET target sphingosine-1-phosphate receptor-1 (S1PR1) is among the genes whose mRNA expression is upregulated in Type 2 compared to Type 1 patients (Bowen et al., 2019). As a preliminary study to validate this PET target, S1PR1 protein expression was assessed by receptor autoradiography and immunohistochemistry in the DLPFC from schizophrenic patients classified as Type 1 or Type 2 based on their DLPFC transcriptomes and from controls. S1PR1 protein expression is upregulated in Type 2 compared to Type 1 (p < 0.05) supporting the possibility that positron emission tomography (PET) can be used as a clinical test to distinguish these subgroups of schizophrenic patients during life.


Sign in / Sign up

Export Citation Format

Share Document